2 hours ago
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo. NanoViricides said its proposal for the Phase II trial has already been... Read more.
Owner: University of Minnesota through the Office of the Vice President for Research
Owner: Mikel Amigot
Owner: Rajeev Chandrasekhar through Jupiter Capital Pvt Ltd & Asianxt Digital Technologies Pty Ltd
More from Asianet Newsable
Owner: Rajeev Chandrasekhar through Jupiter Capital Pvt Ltd & Asianxt Digital Technologies Pty Ltd
Owner: Rajeev Chandrasekhar through Jupiter Capital Pvt Ltd & Asianxt Digital Technologies Pty Ltd
Owner: Rajeev Chandrasekhar through Jupiter Capital Pvt Ltd & Asianxt Digital Technologies Pty Ltd
Search & Explore
Search the news with more context, not more noise.
Today's Media Watch
Your daily guide to the stories shaping media, journalism, and public trust.
Who Owns the Narrative?
See the impact of media framing through real-world case studies.
The EU-Mercosur
Free-trade agreements divide opinion. The EU-Mercosur deal sparked conflicting headlines, reflecting debates over prices, industry, environment, and self-sufficiency.
COVID Vaccinations
This analysis of COVID vaccination coverage shows how ideology, ownership, and political framing shape media narratives, influencing both what we think and how we think.
Greenland
This case study explores the Greenland acquisition scenario as a real-world media literacy stress test, revealing how ideology, ownership, and political framing shape the stories we consume.
Learn About Our Fact-Based Transparency System
Our proprietary bias labels help you understand each outlet’s political orientation, editorial independence, and credibility based on factors like ownership, funding, affiliations, content, and media freedom. Learn more in the Perspectify FAQ.
Learn more
